AmyriAD to Present Clinical and Preclinical Data at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

The Company's lead drug candidate, AD101, is a small molecule under development for the treatment of Alzheimer's Disease AD101 is set to enter Phase 3 clinical trials in 2023 LOS ANGELES, Nov. 29, 2022 /PRNewswire/ -- AmyriAD Therapeutics (AmyriAD) a privately held, late clinical-stage...

Click to view original post